Lead Product(s): PEP-010
Therapeutic Area: Oncology Product Name: PEP-010
Highest Development Status: IND Enabling Product Type: Peptide
Partner/Sponsor/Collaborator: Italian Angels for Growth
Deal Size: $3.5 million Upfront Cash: Undisclosed
Deal Type: Series A Financing April 22, 2021
PEP-Therapy will use the funds to progress the clinical development of PEP-010, PEP-Therapy's lead Cell Penetrating & Interfering Peptide (CP&IP), for the treatment of advanced solid tumors.